Secondary Logo

Journal Logo

Review Articles

Linking Cellular Metabolism to Epigenetics in Melanoma

Guo, Wei-Nan; Li, Chun-Ying

Author Information
International Journal of Dermatology and Venereology: September 2021 - Volume 4 - Issue 3 - p 168-173
doi: 10.1097/JD9.0000000000000191
  • Open

Abstract

Introduction

Melanoma originates from epidermal melanocytes and is the most malignant form of skin cancer, with an increasing incidence worldwide. Although recent advances in targeted therapy and immunotherapy have brought revolutionary progress in the prognosis of patients with advanced melanoma, the survival remains suboptimal,1 indicating the complexity of melanoma etiology and pathogenesis that requires more in-depth investigation. Apart from the known genetic mutations (such as V-raf murine sarcoma viral oncogene homolog B [BRAF], neuroblastoma RAS viral oncogene homolog [NRAS], and phosphatase and tensin homolog [PTEN] mutations) closely associated with ultraviolet radiation or other environmental risk factors that contribute to melanoma carcinogenesis, the remodeling of epigenetic modification has been well documented to orchestrate the malignant behaviors of tumor cells and anti-tumor immunity, emerging as an irreversible tumorigenic event that is more preventable and treatable with medications.2-3 Epigenetic modification refers the heritable changes in gene expression without an alteration in genome sequence. The main paradigms of epigenetic modification including DNA methylation, histone modification and non-coding RNAs. To be specific, DNA methylation is the process of the addition of a methyl group to the 5 position of cytosine by DNA methyltransferase to form 5 methylcytosine (5-mc). In addition, histone modification is defined as a series of modifications occuring on the N-terminal “tails” of hitones, including histone acetylation, methylation and ubiquitination. What's more, non-coding RNAs are alternative type epigenetic regulation involving lncRNAs, microRNAs and circRNAs. The dysregulation of epigenetics in cancer has a broad-spectrum impact on biological activities,4 and recent studies by other groups and our laboratory have reported that disorders of cellular metabolism (including autophagy, mitochondrial function, and the oncometabolite acetyl-CoA) that are related to epigenetic malfunction play a pivotal role in melanoma progression.5-6 Therefore, targeted metabolism-associated epigenetic modulators may be a potential novel approach for melanoma therapy.

This review was conducted by searching PubMed and Web of Science for original research artilces in English. By taking epigenetics (espeically DNA methylation, histone modifiation and non-coding RNA), metabolism (especially autophagy, mitochondiral function and lipid metabolism) and melanoma as key words, we mainly emphasized on the advances of this field from 2016.1.1 to 2020.12.30. Data were independently reviewed by two researchers and underwent thematic analysis by the research team.

The paradoxical role of autophagy in melanoma and its epigenetic regulators

Autophagy is a dynamic metabolic process that delivers intracellular proteins and organelles into autolysosomes for digesting and recycling. The pathologic role of autophagy in melanoma remains unclarified, and the paradoxicality is probably attributable to tumor stage and genetic background. Liu et al. first detected the autophagy marker ATG5 and found that its level is lowered in early-stage melanomas compared with nevi; this downregulation of ATG5 and the autophagy level prevents oncogene-induced senescence in melanocytes to facilitate malignant transformation.7-8 However, in an established genetically-engineered mouse model of melanoma driven by oncogenic BRAF and PTEN tumor suppressor deficiency, Autophagy-related protein 7 (ATG7) gene deletion reportedly restrains tumor growth and extends survival by amplifying oxidative stress and inducing cell senescence in tumors.9 To further investigate these contrary reports, our laboratory systemically examined the autophagy markers LC3 and p62 in melanoma tissues at different clinical stages, and revealed that the autophagy level is downregulated in primary melanomas and upregulated in metastatic lesions.5 Moreover, our data demonstrated the bimodal role played by autophagy that suppresses melanoma growth at the early stage, but acts as an oncogenic factor at the advanced stage both in vitro and in vivo.5 The potentiated autophagy level endows melanoma cells with a high capacity for invasion and migration, which enables the formation of metastases in lung and liver by reshaping the cytoskeleton.10 In addition, the latest research reported that autophagy affects tumor development in a manner dependent on the PTEN status. ATG7 deletion promotes the onset of melanomas in mice harboring only the BRAF mutation, but not in mice hemizygous for PTEN.11 Further investigation is needed to determine whether the effect of autophagy is associated with alternative clinicopathological factors in addition to stage and genetic mutations.

Studies have shown that multiple epigenetic modifiers are responsible for the dysregulation of autophagy. The loss of ATG5 protein at the early stage occurs due to hypermethylation of its promoter.7 Our laboratory showed that the bimodal level of autophagy is paralleled with upstream Type I insulin-like growth factor receptor-Akt signaling that is silenced by histone deacetylase Sir2-related protein type 6 (SIRT6), and that SIRT6 expression level also fluctuates during melanoma progression.5 Targeting SIRT6 also exerts a bimodal function on melanoma growth similar to that of autophagy intervention.5 Furthermore, we performed genome-wide transcriptional analysis to reveal the mRNA expression profile of melanomas, and found that runt-related transcription factor 2 induces the downregulation of miR-23a, which contributes to autophagy activation in metastatic melanoma by relieving its suppression of Atg12.10 Other studies also report that the dysregulation of miRNA is a crucial epigenetic event in trigging the disorder of melanoma cell autophagy.12–14 Overall, the research suggests that DNA methylation enzymes, histone acetylation modifiers, and miRNAs are promising targets for autophagy intervention as melanoma therapy (Fig. 1).

Figure 1
Figure 1:
Key epigenetic regulators of the fluctuating autophagy level in melanoma at different clinical stages. MM: melanoma; ATG5: autophagy-related protein 5; SIRT6: Sir2-related protein type 6; IGF1R: type I insulin-like growth factor receptor; mTOR: mammalian target of rapamycin; Runx2: runt-related transcription factor 2.

Oncogenic mitochondrial function potentiated by histone acetylation and non-coding RNA

The mitochondrion is a crucial organelle responsible for producing ATP and metabolic intermediates via oxidative phosphorylation. Mitochondrial function is generally repressed as a result of the Warburg effect in cancer.15 However, Vazquez et al.16 reported that a subset of melanomas defined by a relatively high endogenous PGC1α expression level show increased mitochondrial capacity and are more resistant to oxidative stress, and that PGC1α deficiency renders melanoma cells more susceptible to reactive oxygen species (ROS)-inducing drugs. Thus, the acquisition of the mitochondrial genome is capable of potentiating the respiratory function and tumorigenic potential.17 There is a close relationship between mitochondrial function and currently available targeted therapy and immunotherapy. In particular, increased mitochondrial biogenesis orchestrated by transcription factor a, mitochondrial (TFAM) mediates the adaptive resistance to MAPK inhibitors in BRAF-mutant melanomas.18 Furthermore, proteomics analysis of clinical samples reveals that higher oxidative phosphorylation and lipid metabolism in mitochondria dictates the response to immunotherapy by elevating antigen presentation and increasing melanoma cell immunogenicity.19 Based on these findings, multiple agents targeting mitochondrial function and oxidative phosphorylation have proven to have high potential in restraining tumor progression and synergizing with targeted therapy.20–22

Transcriptional cascades govern the activation of mitochondrial regulators and downstream components of oxidative phosphorylation machinery in melanoma.23-24 However, the epigenetic regulation mechanism remains poorly defined. Our results proved that the transcriptional cascade Microphthalmia-associated transcription factor (MITF)-Peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC1α) is regulated by p300-mediated histone acetylation. Pharmacological inhibition of p300 suppresses the expression of the MITF-PGC1α axis and downstream mitochondrial function, paralleled with the downregulation of histone acetylation.6 Chromatin immunoprecipitation assay reveals direct binding of acetylated histone to the promoter of MITF.6 In addition, a recent report demonstrated that long non-coding RNA SAMMSON is amplified in melanoma under the control of the lineage-specific transcription factor SRY-box transcription factor 10 (SOX10).25 Further study demonstrated that SAMMSON directly interacts with p32 to increase its mitochondrial targeting and pro-oncogenic function.25 The knockdown of SAMMSON disrupts vital mitochondrial functions in cancer cells, which is therefore expected to deliver highly effective and tissue-restricted anti-melanoma therapeutic responses.25 Taken together, the targeting of mitochondrial function through histone acetylation or non-coding RNA has great therapeutic potential in the management of melanoma (Fig. 2).

Figure 2
Figure 2:
Involvement of histone acetylation and lncRNA in the regulation of mitochondrial biogenesis and oxidative phosphorylation in melanoma, and the resultant effect on melanoma progression, targeted therapy, and immunotherapy. MITF: microphthalmia-associated transcription factor; PGC1α: PPAR-gamma co-activator-1α; SOX10: SRY-related HMG-box 10 protein.

Oncometabolite acetyl-coenzyme A connects cell metabolism to epigenetics

Autophagy and mitochondrial metabolism are two critical metabolic processes that occur in cytoplasm and mitochondria, respectively, both of which are sensitive to the alteration of the intracellular energy status. Acetyl-coenzyme A (Ac-CoA) is a central metabolic intermediate, and its abundance in distinct subcellular compartments reflects the general energetic state of the cell.26 In particular, disturbance of the intracellular Ac-CoA level is directly coupled to cellular autophagic flux and oxidative phosphorylation27–29 as a critical nexus of multiple biological processes. More importantly, Ac-CoA is the sole donor of the acetyl group for acetylation. Nuclear Ac-CoA-mediated histone acetylation fluctuates during the cell cycle and promotes gene transcription via the relaxation of chromatin.26 Therefore, Ac-CoA acts as the second messenger connecting cell metabolism to histone acetylation-mediated epigenetics. Recent studies have revealed that the intracellular Ac-CoA content and histone acetylation increase in carcinogenesis and tumor progression under the control of oncogenic factors such as Akt.30 Multiple Ac-CoA-producing rate-limiting enzymes like ATP-citrate lyase (ACLY) and pyruvate kinase, muscle are reportedly hyperactivated in cancers.31-32 Moreover, the nuclear translocation of pyruvate dehydrogenase complex from mitochondria also potentiates nuclear Ac-CoA generation and histone acetylation and is implicated in cancer pathogenesis.33 These reports emphasize the role of Ac-CoA as an oncometabolite through its epigenetic modification function.

We recently investigated the role of the Ac-CoA-producing enzyme ACLY, which is the node of glucose and lipid metabolism.34 ACLY is prominently activated in melanoma and its expression is highly associated with patient survival. In particular, upregulated ACLY expression promotes Ac-CoA production to enhance histone acetylation in an acetyltransferase p300-dependent manner, which contributes to mitochondrial oxidative phosphorylation and tumor growth.6 To the best of our knowledge, the above-mentioned investigation by our group was the first to reveal the pivotal role of Ac-CoA-mediated crosstalk between different metabolic processes in tumors and demonstrate that ACLY and p300 are promising therapeutic targets associated with metabolism and epigenetics in melanoma therapy (Fig. 3).

Figure 3
Figure 3:
Schematic presentation of the mechanism underlying the facilitative role of ACLY in mitochondrial function via acetyl-coenzyme A (Ac-CoA) in melanoma. ACLY expression is upregulated in melanoma, followed by an increase in Ac-CoA content, enhancement of P300 activity, and increase in histone acetylation at the MITF promoter. This leads to the transcriptional activation of the MITF-PGC1α axis and subsequent mitochondrial biogenesis. ACLY: ATP-citrate lyase; PGC1 α: peroxisome proliferator-activated receptor gamma coactivator 1 α; MITF: microphthalmia-associated transcription factor.

Future perspectives

Although the linkage between epigenetics and metabolism in melanoma pathogenesis has been preliminarily revealed by our group and some other investigations, there are several limitations and questions waiting to be solved or answered. To be specific, genome-wide transcriptional analysis or proteomics analysis should be employed to systemically testify the regulatory relationship between these two crucial hallmark characteristics. In addition, more paradigms of cell metabolism and epigenetic modifications like amino acid metabolism, nucleotide metabolism, histone methylation, and other forms of histone modifications should also be emphasized and taken into consideration in further studies. What's more, more pre-clinical animal models need to be used to elucidate the translational potential of targeting the crosstalk between metabolism and epigenetics in melanoma therapy.

In summary, reports from other groups and our laboratory have provided evidence revealing the interplay between metabolism and epigenetic modification in the pathogenesis of melanoma. The above-mentioned epigenetic regulators of autophagy, mitochondrial function, and Ac-CoA production might be valuable as potential therapeutic targets for melanoma treatment. This therapeutic approach warrants future investigation.

Acknowledgments

The authors are grateful to Dr. Jian-Ru Chen for revising the manuscript.

Source of funding

The research leading to these results has received funding from the National Natural Science Foundation of China (No. 81625020, No. 81902791) and the Xijing Hospital (No. 2019cyjhgwn).

References

[1]. Lo JA, Fisher DE. The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Science 2014;346(6212):945–949. doi:10.1126/science.1253735.
[2]. Jones PA, Issa JP, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev Genet 2016;17(10):630–641. doi:10.1038/nrg.2016.93.
[3]. Mohammad HP, Barbash O, Creasy CL. Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. Nat Med 2019;25(3):403–418. doi:10.1038/s41591-019-0376-8.
[4]. Sun L, Zhang H, Gao P. Metabolic reprogramming and epigenetic modifications on the path to cancer. Protein Cell 2021;doi:10.1007/s13238-021-00846-7. Epub ahead of print.
[5]. Wang L, Guo W, Ma J, et al. Aberrant SIRT6 expression contributes to melanoma growth: role of the autophagy paradox and IGF-AKT signaling. Autophagy 2018;14(3):518–533. doi:10.1080/15548627.2017.1384886.
[6]. Guo W, Ma J, Yang Y, et al. ATP-citrate lyase epigenetically potentiates oxidative phosphorylation to promote melanoma growth and adaptive resistance to MAPK inhibition. Clin Cancer Res 2020;26(11):2725–2739. doi:10.1158/1078-0432.CCR-19-1359.
[7]. Liu H, He Z, von Rutte T, et al. Down-regulation of autophagy-related protein 5 (ATG5) contributes to the pathogenesis of early-stage cutaneous melanoma. Sci Transl Med 2013;5(202):202ra123. doi:10.1126/scitranslmed.3005864.
[8]. Liu H, He Z, Simon HU. Autophagy suppresses melanoma tumorigenesis by inducing senescence. Autophagy 2014;10(2):372–373. doi:10.4161/auto.27163.
[9]. Xie X, Koh JY, Price S, et al. Atg7 overcomes senescence and promotes growth of BrafV600E-driven melanoma. Cancer Discov 2015;5(4):410–423. doi:10.1158/2159-8290.CD-14-1473.
[10]. Guo W, Wang H, Yang Y, et al. Down-regulated miR-23a contributes to the metastasis of cutaneous melanoma by promoting autophagy. Theranostics 2017;7(8):2231–2249. doi:10.7150/thno.18835.
[11]. Rosenfeldt MT, O’Prey J, Lindsay CR, et al. Loss of autophagy affects melanoma development in a manner dependent on PTEN status. Cell Death Differ 2021;28(4):1437–1439. doi:10.1038/s41418-021-00746-7.
[12]. Guo Y, Shi W, Fang R. MiR18a5p promotes melanoma cell proliferation and inhibits apoptosis and autophagy by targeting EPHA7 signaling. Mol Med Rep 2021;23(1):79. doi:10.3892/mmr.2020.11717.
[13]. Yu Y, Xiang N, Lin M, et al. miR-26a sensitizes melanoma cells to dabrafenib via targeting HMGB1-dependent autophagy pathways. Drug Des Devel Ther 2019;13:3717–3726. doi:10.2147/DDDT.S225671.
[14]. Tang H, Xu X, Xiao W, et al. Silencing of microRNA-27a facilitates autophagy and apoptosis of melanoma cells through the activation of the SYK-dependent mTOR signaling pathway. J Cell Biochem 2019;120(8):13262–13274. doi:10.1002/jcb.28600.
[15]. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324(5930):1029–1033. doi:10.1126/science.1160809.
[16]. Vazquez F, Lim JH, Chim H, et al. PGC1alpha expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 2013;23(3):287–301. doi:10.1016/j.ccr.2012.11.020.
[17]. Tan AS, Baty JW, Dong LF, et al. Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA. Cell Metab 2015;21(1):81–94. doi:10.1016/j.cmet.2014.12.003.
[18]. Zhang G, Frederick DT, Wu L, et al. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest 2016;126(5):1834–1856. doi:10.1172/JCI82661.
[19]. Harel M, Ortenberg R, Varanasi SK, et al. Proteomics of melanoma response to immunotherapy reveals mitochondrial dependence. Cell 2019;179(1):236–250.e18. doi:10.1016/j.cell.2019.08.012.
[20]. Vashisht Gopal YN, Gammon S, Prasad R, et al. A novel mitochondrial inhibitor blocks MAPK pathway and overcomes MAPK inhibitor resistance in melanoma. Clin Cancer Res 2019;25(21):6429–6442. doi:10.1158/1078-0432.CCR-19-0836.
[21]. Ashton TM, McKenna WG, Kunz-Schughart LA, et al. Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res 2018;24(11):2482–2490. doi:10.1158/1078-0432.CCR-17-3070.
[22]. Gelato KA, Schockel L, Klingbeil O, et al. Super-enhancers define a proliferative PGC-1alpha-expressing melanoma subgroup sensitive to BET inhibition. Oncogene 2018;37(4):512–521. doi:10.1038/onc.2017.325.
[23]. Abbate F, Badal B, Mendelson K, et al. FBXW7 regulates a mitochondrial transcription program by modulating MITF. Pigment Cell Melanoma Res 2018;31(5):636–640. doi: 10.1111/pcmr.12704.
[24]. Brown K, Yang P, Salvador D, et al. WNT/beta-catenin signaling regulates mitochondrial activity to alter the oncogenic potential of melanoma in a PTEN-dependent manner. Oncogene 2017;36(22):3119–3136. doi:10.1038/onc.2016.450.
[25]. Leucci E, Vendramin R, Spinazzi M, et al. Melanoma addiction to the long non-coding RNA SAMMSON. Nature 2016;531(7595):518–522. doi:10.1038/nature17161.
[26]. Pietrocola F, Galluzzi L, Bravo-San Pedro JM, et al. Acetyl coenzyme A: a central metabolite and second messenger. Cell Metab 2015;21(6):805–821. doi:10.1016/j.cmet.2015.05.014.
[27]. Liu X, Cooper DE, Cluntun AA, et al. Acetate production from glucose and coupling to mitochondrial metabolism in mammals. Cell 2018;175(2):502–513.e13. doi:10.1016/j.cell.2018.08.040.
[28]. Schroeder S, Pendl T, Zimmermann A, et al. Acetyl-coenzyme A: a metabolic master regulator of autophagy and longevity. Autophagy 2014;10(7):1335–1337. doi:10.4161/auto.28919.
[29]. Marino G, Pietrocola F, Eisenberg T, et al. Regulation of autophagy by cytosolic acetyl-coenzyme A. Mol Cell 2014;53(5):710–725. doi:10.1016/j.molcel.2014.01.016.
[30]. Lee JV, Carrer A, Shah S, et al. Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation. Cell Metab 2014;20(2):306–319. doi:10.1016/j.cmet.2014.06.004.
[31]. Luo W, Semenza GL. Emerging roles of PKM2 in cell metabolism and cancer progression. Trends Endocrinol Metab 2012;23(11):560–566. doi:10.1016/j.tem.2012.06.010.
[32]. Zaidi N, Swinnen JV, Smans K. ATP-citrate lyase: a key player in cancer metabolism. Cancer Res 2012;72(15):3709–3714. doi:10.1158/0008-5472.CAN-11-4112.
[33]. Sutendra G, Kinnaird A, Dromparis P, et al. A nuclear pyruvate dehydrogenase complex is important for the generation of acetyl-CoA and histone acetylation. Cell 2014;158(1):84–97. doi:10.1016/j.cell.2014.04.046.
[34]. Wellen KE, Hatzivassiliou G, Sachdeva UM, et al. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 2009;324(5930):1076–1080. doi:10.1126/science.1164097.
Keywords:

melanoma; metabolism; epigenetics; autophagy; histone acetylation; miRNAs; lipid metabolism; targeted therapy

Copyright © 2021 Hospital for Skin Diseases (Institute of Dermatology), Chinese Academy of Medical Sciences, and Chinese Medical Association, published by Wolters Kluwer, Inc.